A pertinent article has been posted on Twitter by Dr Elisa Perego. I've quickly gone through it, so need to read it properly, but the following paragraph particularly attracted my attention:
According to an analysis performed by Lisco et al. in 2021, it was found that patients who suffered a more severe form of COVID-19 infection had reduced serum-FT3 hormone and FT3 is postulated to be needed to reduce the systemic inflammatory effects that interleukin-6 (IL-6) induces on cytokines. A leading cause of low FT3 levels is sepsis, which suggests that contracting COVID-19 may be correlated with potentially severe systemic inflammatory responses that also increase the overall intensity of the immune response to infections [75]. Thus, modifying/managing pre-existing thyroid diseases may entail T3-replacement therapy to prevent a more severe infection course from COVID-19.
Fn 75: Lisco G, De Tullio A, Jirillo E, Giagulli VA, De Pergola G, Guastamacchia E, Triggiani V: Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects. J Endocrinol Invest. 2021, 44:1801-14. 10.1007/s40618-021-01554-z
Full article, open access:
Long-Term Impacts of COVID-19 on Thyroid Health: Insights From Clinical Studies
MHRA latest advice re vaccines 
Slowly but slowly they are catching up
